Recent events
Recent events tied to this brand in public sources.
Back to profile95 entries · Page 3 of 5
2021
South Africa dispatches first batch of AstraZeneca vaccine doses to the African Union
South Africa dispatched the first batch of its AstraZeneca vaccine doses to the African Union after selling the African Union its supply of one million doses.
2021
Netherlands suspends AstraZeneca vaccine use for people under 60
The Netherlands temporarily suspended use of the AstraZeneca COVID-19 vaccine for people under 60 following the death of a woman who had received a dose.
2021
UK regulator reports blood-clot cases after AstraZeneca vaccine use
The UK regulator said it had identified 30 cases of rare blood-clot events following use of the AstraZeneca COVID-19 vaccine.
2021
RedHill and MSN settle Movantik patent litigation
RedHill Biopharma announced that RedHill, AstraZeneca, Nektar and MSN had entered a settlement and license agreement resolving U.S. patent litigation concerning MSN's application to market a generic version of Movantik. Under the agreement, MSN may not sell a generic version in the U.S. until October 1, 2030, subject to FDA approval, or earlier under certain circumstances.
2021
AstraZeneca announces further EU vaccine delivery delays
AstraZeneca announced further delays to Covid-19 vaccine deliveries to the EU, saying first-quarter deliveries would be reduced again and second-quarter deliveries would very likely also be affected.
2021
EMA investigates blood clot reports involving AstraZeneca’s COVID-19 vaccine
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee was investigating thromboembolic events reported in people who received AstraZeneca’s COVID-19 vaccine. The agency said its review was ongoing and that the vaccine’s benefits currently outweighed the risks.
2021
AstraZeneca and IDT Biologika form vaccine manufacturing partnership
AstraZeneca and IDT Biologika formed a manufacturing partnership to increase production of AstraZeneca's COVID-19 vaccine in the EU. They intend to jointly invest in additional drug-substance capacity and plan investments at IDT's Dessau site.
2021
Gerresheimer receives AstraZeneca sustainability award for 2020
Gerresheimer's Horšovský Týn and Pfreimd production plants received Gold certificates from AstraZeneca for 2020 under its supplier sustainability program.
2021
Philippine FDA authorizes AstraZeneca vaccine for emergency use
The Philippines' Food and Drug Administration granted emergency use authorization to the COVID-19 vaccine made by AstraZeneca.
2021
Pfizer and AstraZeneca reduce vaccine deliveries to Italy
Italy's health deputy minister said Pfizer and AstraZeneca reduced vaccine supplies, delaying the vaccination schedule for people aged 80 and over by four weeks and for other age groups by six to eight weeks.
2021
AstraZeneca files suit over 340B advisory opinion
AstraZeneca Pharmaceuticals LP filed a complaint in Delaware federal court against the Department of Health and Human Services, seeking to have the agency’s advisory opinion on 340B discounts to contract pharmacies declared invalid.
2021
Recombinetics and AstraZeneca announce NF1 research collaboration
Recombinetics announced a research collaboration with AstraZeneca to assess selumetinib for cutaneous neurofibromas using Surrogen's NF1 preclinical platform.
2020
U.K. approves Oxford-AstraZeneca COVID-19 vaccine
The U.K. became the first country to approve the COVID-19 vaccine developed by Oxford University and AstraZeneca.
2020
FDA approves Tagrisso for adjuvant NSCLC therapy
The FDA approved osimertinib (Tagrisso, AstraZeneca) as adjuvant therapy for patients with non-small cell lung cancer with EGFR mutations. The new indication covers patients with specified EGFR mutations after tumor resection.
2020
AstraZeneca announces plan to acquire Alexion
AstraZeneca announced plans to acquire Alexion for approximately $39 billion. The boards of both companies approved the acquisition, which was expected to close in the third quarter of 2021 subject to regulatory clearances and shareholder approval.
2020
AstraZeneca partners on AZD1222–Sputnik V combination trial
AstraZeneca partnered with the Gamaleya Research Institute, RDIF and R-Pharm to conduct a clinical trial assessing the safety and immunogenicity of combining AZD1222 and Sputnik V vaccines.
2020
AstraZeneca plans combined-vaccine clinical trials with Sputnik V
AstraZeneca said it would explore with Russia's Gamaleya Institute whether its experimental COVID-19 vaccine could be combined with Sputnik V in clinical trials. The trials were expected to start by the end of the year.
2020
Covishield trial volunteer sues Serum Institute over alleged adverse reaction
A 40-year-old Covishield trial volunteer sued Serum Institute of India for ₹5 crore, alleging that the vaccine caused an adverse reaction including neurological impairment. The hospital's institutional ethics committee reportedly concluded that the adverse reaction was not due to the study vaccine.
2020
FDA approves additional Imfinzi dosing option in the US
The FDA approved an additional Imfinzi dosing option in the United States: a fixed 1,500 mg dose every four weeks for approved indications of unresectable Stage III non-small cell lung cancer.
2020
AstraZeneca faces criticism over U.S. vaccine-trial transparency
The article reports calls for AstraZeneca and the FDA to explain why the U.S. clinical trial of AstraZeneca's COVID-19 vaccine remained paused. Critics said greater transparency was needed; the article says the company had not explained why the trial had not resumed.